Veru Inc (VERU)

$0.54 -0.01 (-2.02%)
Market Cap 80.38M
Revenue (ttm) 16.89M
Net Income (ttm) -37.80M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -223.80%
Debt to Equity Ratio 0.00
Volume 755,400
Avg Vol 1,774,710
Day's Range N/A - N/A
Shares Out 146.38M
Stochastic %K 42%
Beta -0.69
Analysts Strong Sell
Price Target $2.80

Latest News on VERU

Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit

Apr 16, 2025, 8:30 AM EDT - 9 days ago

Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit

Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference

Mar 31, 2025, 8:30 AM EDT - 25 days ago

Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference

Veru Inc (VERU) Q1 2025 Earnings Call Transcript

Feb 13, 2025, 2:35 PM EST - 2 months ago

Veru Inc (VERU) Q1 2025 Earnings Call Transcript

Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

Feb 13, 2025, 6:30 AM EST - 2 months ago

Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

Veru Shares Tumble Despite Enobosarm's Lean Muscle Preservation Breakthrough

Jan 27, 2025, 10:34 AM EST - 3 months ago

Veru Shares Tumble Despite Enobosarm's Lean Muscle Preservation Breakthrough

Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction

Jan 27, 2025, 6:30 AM EST - 3 months ago

Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction

Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business

Dec 31, 2024, 8:30 AM EST - 4 months ago

Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business

Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders

Nov 26, 2024, 8:30 AM EST - 5 months ago

Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders

Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek

Nov 5, 2024, 8:30 AM EST - 6 months ago

Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek

Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss

Oct 21, 2024, 8:30 AM EDT - 6 months ago

Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss

Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress

Oct 16, 2024, 8:30 AM EDT - 6 months ago

Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress

Veru to Present at the 2024 Cantor Global Healthcare Conference

Sep 11, 2024, 8:30 AM EDT - 8 months ago

Veru to Present at the 2024 Cantor Global Healthcare Conference

Veru Inc. (VERU) Q3 2024 Earnings Call Transcript

Aug 10, 2024, 8:39 AM EDT - 9 months ago

Veru Inc. (VERU) Q3 2024 Earnings Call Transcript

Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results

Aug 8, 2024, 6:30 AM EDT - 9 months ago

Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results

Veru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024

Aug 1, 2024, 8:30 AM EDT - 9 months ago

Veru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024

Veru to Participate in the BTIG Virtual Biotechnology Conference

Jul 29, 2024, 8:30 AM EDT - 9 months ago

Veru to Participate in the BTIG Virtual Biotechnology Conference

Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism

Jul 2, 2024, 8:30 AM EDT - 10 months ago

Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism

Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions

Jun 24, 2024, 8:30 AM EDT - 10 months ago

Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions

Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024

Jun 18, 2024, 4:05 PM EDT - 11 months ago

Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024

Veru Reminds Shareholders to Vote in Advance of Tomorrow's Deadline for 2024 Annual Meeting of Shareholders

Jun 17, 2024, 4:45 PM EDT - 11 months ago

Veru Reminds Shareholders to Vote in Advance of Tomorrow's Deadline for 2024 Annual Meeting of Shareholders

Veru to Present at the American Diabetes Association's 84th Scientific Sessions

Jun 10, 2024, 8:30 AM EDT - 11 months ago

Veru to Present at the American Diabetes Association's 84th Scientific Sessions

Veru to Present at the Jefferies Global Healthcare Conference

May 22, 2024, 8:30 AM EDT - 1 year ago

Veru to Present at the Jefferies Global Healthcare Conference

Veru Announces Steven B. Heymsfield M.D.

May 15, 2024, 8:30 AM EDT - 1 year ago

Veru Announces Steven B. Heymsfield M.D.

Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week

May 14, 2024, 8:30 AM EDT - 1 year ago

Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week

Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program

May 8, 2024, 6:30 AM EDT - 1 year ago

Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program

Veru to Present at the GLP-1 Based Therapeutics Summit

May 2, 2024, 8:30 AM EDT - 1 year ago

Veru to Present at the GLP-1 Based Therapeutics Summit

Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024

May 1, 2024, 8:30 AM EDT - 1 year ago

Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024

Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Apr 30, 2024, 8:30 AM EDT - 1 year ago

Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11

Apr 25, 2024, 8:30 AM EDT - 1 year ago

Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11

Veru Reschedules Annual Meeting of Shareholders

Mar 22, 2024, 4:05 PM EDT - 1 year ago

Veru Reschedules Annual Meeting of Shareholders

Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss

Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

Feb 27, 2024, 7:15 PM EST - 1 year ago

Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss

Feb 20, 2024, 8:30 AM EST - 1 year ago

Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss

Veru Inc. (VERU) Q1 2024 Earnings Call Transcript

Feb 8, 2024, 1:36 PM EST - 1 year ago

Veru Inc. (VERU) Q1 2024 Earnings Call Transcript

Veru Reports Fiscal 2024 First Quarter Financial Highlights

Feb 8, 2024, 6:30 AM EST - 1 year ago

Veru Reports Fiscal 2024 First Quarter Financial Highlights

Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs

Feb 6, 2024, 8:30 AM EST - 1 year ago

Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs

Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 31, 2024, 8:30 AM EST - 1 year ago

Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024

Jan 25, 2024, 8:30 AM EST - 1 year ago

Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024

Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss

Jan 8, 2024, 8:30 AM EST - 1 year ago

Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss

Veru to Host Investor Call on January 4th, 2024 to Discuss Recent Financing and Strategy to Prioritize the Development of Enobosarm as a Combination Treatment to Prevent Muscle Loss and Augment Fat Loss Associated with Weight Loss GLP-1 Drugs

Dec 19, 2023, 8:30 AM EST - 1 year ago

Veru to Host Investor Call on January 4th, 2024 to Discuss Recent Financing and Strategy to Prioritize the Development of Enobosarm as a Combination Treatment to Prevent Muscle Loss and Augment Fat Loss Associated with Weight Loss GLP-1 Drugs

Veru Announces Pricing of Public Offering of Common Stock

Dec 14, 2023, 9:00 AM EST - 1 year ago

Veru Announces Pricing of Public Offering of Common Stock

Veru Announces Proposed Public Offering of Common Stock

Dec 13, 2023, 4:01 PM EST - 1 year ago

Veru Announces Proposed Public Offering of Common Stock

Veru Reports Muscle Data from 5 Clinical Studies of Enobosarm that Support the Advancement of Enobosarm in Combination with Weight-Loss GLP-1 Drugs, Ozempic®, Wegovy®, or Mounjaro®, to Optimize Weight Loss by Preventing Muscle Wasting and Further Increasi

Oct 4, 2023, 8:30 AM EDT - 1 year ago

Veru Reports Muscle Data from 5 Clinical Studies of Enobosarm that Support the Advancement of Enobosarm in Combination with Weight-Loss GLP-1 Drugs, Ozempic®, Wegovy®, or Mounjaro®, to Optimize Weight Loss by Preventing Muscle Wasting and Further Increasi

Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication: Hospitalized Adult Patients with Any Type of Viral Acute Respiratory Distress Syndrome (ARDS)

Sep 26, 2023, 8:30 AM EDT - 1 year ago

Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication: Hospitalized Adult Patients with Any Type of Viral Acute Respiratory Distress Syndrome (ARDS)

Veru to Participate in Fireside Chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on September 28th, 2023

Sep 20, 2023, 8:30 AM EDT - 1 year ago

Veru to Participate in Fireside Chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on September 28th, 2023

Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer

Sep 11, 2023, 7:00 AM EDT - 1 year ago

Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer

Veru to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 11th, 2023

Aug 30, 2023, 8:30 AM EDT - 1 year ago

Veru to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 11th, 2023

Veru Reports Fiscal 2023 Third Quarter Financial Results

Aug 10, 2023, 6:30 AM EDT - 1 year ago

Veru Reports Fiscal 2023 Third Quarter Financial Results